Improved Outcomes for Older Children, Adolescents, and Young Adults With Neuroblastoma in the Post‐Immunotherapy Era: An Updated Report From the International Neuroblastoma Risk Group

Pediatric Blood & Cancer 2026 Open access

Read full text
Authors: Rebecca Deyell, Kavitha Srivatsa, Paola Angelini, Pei‐Chi Kao, Brady Payne, Arlene Naranjo, S Castelli, Miho Kato, Miki Ohira, Ulriche Pöetschger, Y P Mossé, Lucas Moreno
+3 more Meredith S. Irwin, Ramya Ramanujachar, Wendy B. London
DOI: 10.1002/1545-5017.70124
Cited by: 2
References: 15

Abstract

BACKGROUND: We describe clinical and biologic characteristics of neuroblastoma in older children, adolescents, and young adults (OCAYA); describe survival outcomes in the post-immunotherapy era; and identify if there is an age cut-off that best discriminates outcomes. METHODS: Patients diagnosed with neuroblastoma at ≥547 days between 2003 and 2022 from the International Neuroblastoma Risk Group Data Commons were compared by age subgroups. Recursive partitioning, dividing younger versus older at all monthly cut-points between 18 months and 15 years, was undertaken using Cox regression models of event-free survival (EFS), overall survival (OS), and OS post-relapse (OSPR). Kaplan-Meier curves of clinical/biologic subgroups were compared with log-rank tests. RESULTS: 7,835 patients met inclusion criteria: 18 months to

Fields of Study & Subjects

Neuroblastoma Research and Treatments Cancer Hypoxia and Metabolism Virus-based gene therapy research

Publication details

Journal / source
Pediatric Blood & Cancer
Publisher
Wiley
Volume
73
Issue
4
Pages
e70124–e70124
Publication date
16 January 2026
Language
EN